On Wednesday, 19 August, Moderna announced that its personalised mRNA cancer therapy had succeeded in a Phase 3 trial. The news sent the stock sharply higher. Shares rose 177%, more than doubling in a single session and closing above $174. Merck, which partnered with Moderna on the programme, also gained, rising 12.6%.
The reaction did not last equally for both companies. By Thursday afternoon, Moderna had fallen as much as 25%, trading near $129, and eventually closed down around 19%. Nearly $18 billion in market value disappeared from the stock. Merck, meanwhile, ended the same session down just 0.57%.
The trial result itself had not changed. The same data that sent Moderna higher on Wednesday was still there on Thursday. The difference was how investors viewed each company’s ability to turn that scientific breakthrough into long-term value, defining the price gap between discovery and value.
What the trial showed
Intismeran autogene is a personalised cancer therapy designed around the specific mutations found in an individual patient’s tumour. The treatment aims to train the immune system to recognise and attack those cancer targets.
It is used alongside Merck’s Keytruda, rather than as a replacement.
In the INTerpath-001 trial, the combination met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival in patients with stage IIB to IV melanoma after surgery.
The result marked the first positive late-stage trial for an mRNA-based cancer treatment.
However, one detail stood out. The announcement did not include hazard ratios or detailed efficacy figures. The market moved sharply based on a topline success announcement, before seeing the full data. That meant investors were not only pricing the science, they were also pricing the potential commercial impact.
Same breakthrough, different market value
Moderna created the therapy and owns the underlying mRNA platform. Merck brought Keytruda, regulatory experience and global commercial reach.
Both companies benefited from the result, but investors viewed their opportunities differently.
- For Moderna, the trial created more possibilities. A successful personalised cancer vaccine platform could eventually expand across several cancer types.
- For Merck, the opportunity was more immediate. The treatment could potentially strengthen the Keytruda franchise at a time when the company faces one of the biggest patent expiries in the pharmaceutical industry.
The market was not only asking, “Who created the breakthrough?”
It was asking, “Who is best positioned to monetise it?”
MRK’s clearer path to commercial value
Merck’s challenge is straightforward: replacing revenue from Keytruda before patent protection expires.
Keytruda generated around $25.3 billion in annual sales and remains one of the world’s biggest medicines. US exclusivity expires in December 2028, while government pricing measures under the Inflation Reduction Act begin affecting selected drugs from January 2028.
That gives Merck a clear timeline.
A successful combination therapy using intismeran could help extend the commercial life of Keytruda. Instead of adding a completely separate product, Merck may be able to strengthen an existing treatment platform with a new generation of cancer care.
Investors reacted to that opportunity.
Morgan Stanley upgraded Merck to Overweight and many analysts raised its price target, arguing that pipeline assets including intismeran could help offset pressure from the Keytruda patent expiry.
Merck entered the announcement with a stronger financial base. Keytruda alone generated more than $16 billion in cash flow in the first half of 2026, giving the company greater flexibility to invest, develop and commercialise new treatments.
MRNA needs to turn potential into revenue
The situation looks different for Moderna.
The company owns a valuable platform, but it is still trying to prove that platform can generate sustainable earnings.
In the second quarter of 2026, Moderna reported revenue of $145 million and a net loss of $782 million. Research and development expenses reached $651 million during the quarter, more than four times its revenue.
The company ended June with $6.9 billion in cash and investments, down from $7.5 billion three months earlier. Management expects year-end cash and investments of between $4.7 billion and $5.2 billion.
At the same time, not every mRNA programme has progressed smoothly. Moderna’s norovirus candidate mRNA-1403 failed to meet statistical criteria in its Phase 3 interim analysis.
The cancer therapy result changed the company’s future possibilities, but it did not immediately change the underlying financial picture.
| Moderna | Merck | |
| Main contribution | mRNA platform and personalised therapy | Keytruda, commercial scale and distribution |
| Q2 2026 position | $145m revenue, $782m net loss | Keytruda generated over $16bn in H1 cash flow |
| Value of the data | Creates broader platform potential | Helps protect an existing revenue stream |
| Two-day stock move | +177%, then gave back around a fifth | +12.6%, largely held gains |
Moderna’s opportunity is based on optionality. The company has nine Phase 2 and Phase 3 intismeran trials underway across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma.
If the results translate across multiple cancers, the opportunity becomes significantly larger.
However, optionality breeds uncertainty and harder for markets to value. A company with a promising platform but limited current earnings does not have the same financial anchor as a company with an established commercial product.
The patent cliff reshaping biotech
The Moderna-Merck partnership reflects a broader trend across the pharmaceutical industry.
Around $300 billion of branded pharmaceutical revenue is expected to face patent expiry pressure by 2030. At the same time, biopharma deal activity has accelerated as larger companies look for replacement growth.
The reason is simple: established pharmaceutical companies are not only looking for new science. They are looking for new revenue streams before older ones decline.
That changes the balance between biotech companies and large pharmaceutical firms.
Smaller companies often bring innovation and breakthrough science. Larger companies bring capital, regulatory experience and commercial infrastructure.
The value split between them is often decided long before the breakthrough arrives, when partnerships are first negotiated.
This is why scientific validation does not always mean the inventor captures the largest share of the value.
BioNTech’s reaction showed another side of this dynamic. The company, which is developing its own personalised cancer vaccine programmes, fell 4% on the same day. Investors viewed the result as validation of the technology, but also as evidence of increasing competition.
The risks behind the optimism
All things given, the current market reaction may not tell the full story.
The biggest challenge is manufacturing. Personalised cancer therapies require every dose to be created for a specific patient. Scaling production, maintaining quality and managing logistics remain important questions.
If Moderna solves those challenges, its platform could become a meaningful competitive advantage.
Pricing is another uncertainty. There is no established model for how health systems will reimburse personalised cancer treatments at scale. Strong clinical results do not automatically guarantee commercial success.
There is also a longer-term argument in Moderna’s favour.
If intismeran succeeds across additional cancer types, the value created could eventually be much larger than what investors are currently pricing in. The current difference between Moderna and Merck reflects today’s financial positions, not necessarily the final outcome.
What to watch next
The scientific question has moved forward. The next debate is about execution and value capture.
Several factors will determine what happens next:
- Results from additional trials, particularly in non-small cell lung cancer and bladder cancer, which could show whether the platform works beyond melanoma.
- Regulatory timelines and whether the companies can move quickly towards approval discussions.
- Moderna’s financial position, and whether future funding can be raised on stronger terms after this repricing.
- Future biotech-pharma partnerships, which may show whether innovators are gaining negotiating power.
Proving the science and capturing the economic value of that science are two different achievements. Merck’s gain held because the data had somewhere to go inside a business that already exists. Moderna’s didn’t, because that business is still being built.
One catalyst, two different setups. Moderna trades on event risk, moving hard on trial and regulatory news and drifting in between. Merck carries the same cancer treatment theme through a business already generating billions, which has so far meant smaller moves in both directions.
Track live pricing and market reaction on both MRNA and MRK with VT Markets.
Tap for Trader’s Takeaway
What is the Moderna and Merck cancer vaccine partnership?
Moderna developed the personalised mRNA cancer therapy, while Merck provides Keytruda and commercial expertise. The partnership combines Moderna’s technology with Merck’s oncology capabilities.
Why did Moderna stock rise after its cancer vaccine trial result?
Moderna surged after its personalised mRNA cancer therapy achieved positive Phase 3 results, raising expectations for its future cancer pipeline.
Why did Merck stock benefit from Moderna’s cancer breakthrough?
Merck’s gain was linked to the potential for intismeran to strengthen Keytruda’s franchise and help support future revenue growth.
Why did Moderna and Merck stocks react differently to the same breakthrough?
Moderna represents future platform potential, while Merck offers a clearer commercial path through an established oncology business.
What does the Moderna and Merck stock split reveal about biotech breakthroughs? A successful therapy does not always create equal market value. Commercial scale, revenue visibility and timing can determine who benefits most.
